Skip to main content

Ioxaglate Pregnancy and Breastfeeding Warnings

Brand names: Hexabrix

Ioxaglate Pregnancy Warnings

Use is not recommended unless clearly needed.

US FDA pregnancy category: B

Comment: This drug cross the placental barrier.

Reproduction studies have been performed in rats, and rabbits at doses up to two times the maximum adult human dose and have revealed no evidence of impaired fertility or harm to the fetus. There are no adequate and well controlled studies in pregnant women.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

See references

Ioxaglate Breastfeeding Warnings

Breastfeeding is not recommended during use of this drug.

Excreted into human milk: Yes

Comments:
-The effects in the nursing infant are unknown.
-Use bottle feeding for 24 hours following the administration of this drug.

See references

See also

References for pregnancy information

  1. (2015) "Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc

References for breastfeeding information

  1. (2015) "Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer